Trial · NCT05061446
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission at Week 12 | Placebo | 0 | Percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Remission at Week 12 | Etrasimod 1 mg | 6.7 | Percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Remission at Week 12 | Etrasimod 2 mg | 26.3 | Percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Improvement at Week 12 | Placebo | 0 | Percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Improvement at Week 12 | Etrasimod 1 mg | 6.7 | Percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Improvement at Week 12 | Etrasimod 2 mg | 26.3 | Percentage of participants | ||
| Percentage of Participants Who Achieved Symptomatic Remission at Week 12 | Placebo | 0 | Percentage of participants | ||
| Percentage of Participants Who Achieved Symptomatic Remission at Week 12 | Etrasimod 1 mg | 20.0 | Percentage of participants | ||
| Percentage of Participants Who Achieved Symptomatic Remission at Week 12 | Etrasimod 2 mg | 31.6 | Percentage of participants | ||
| Percentage of Participants Who Achieved Mucosal Healing at Week 12 | Placebo | 0 | Percentage of participants | ||
| Percentage of Participants Who Achieved Mucosal Healing at Week 12 | Etrasimod 1 mg | 6.7 | Percentage of participants | ||
| Percentage of Participants Who Achieved Mucosal Healing at Week 12 | Etrasimod 2 mg | 5.3 | Percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Response at Week 12 | Placebo | 7.1 | Percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Response at Week 12 | Etrasimod 1 mg | 33.3 | Percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Response at Week 12 | Etrasimod 2 mg | 52.6 | Percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Normalization at Week 12 | Placebo | 0 | Percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Normalization at Week 12 | Etrasimod 1 mg | 0 | Percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Normalization at Week 12 | Etrasimod 2 mg | 0 | Percentage of participants | ||
| Number of Participants With Adverse Events According to Severity | Placebo | Grade1 | 5 | Participants | |
| Number of Participants With Adverse Events According to Severity | Etrasimod 1 mg | Grade1 | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05061446/results